npj Breast Cancer (Apr 2024)

Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer

  • Paolo Tarantino,
  • Julieta Leone,
  • Carlos T. Vallejo,
  • Rachel A. Freedman,
  • Adrienne G. Waks,
  • Olga Martínez-Sáez,
  • Ana Garrido-Castro,
  • Filipa Lynce,
  • Nabihah Tayob,
  • Nancy U. Lin,
  • Sara M. Tolaney,
  • Jose P. Leone

DOI
https://doi.org/10.1038/s41523-024-00634-6
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 4

Abstract

Read online

Abstract To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors (p = 0.001 and p < 0.001, respectively). Receipt of chemotherapy was associated with improved breast cancer-specific survival (BCSS, adjusted hazard ratio = 0.70; p = 0.006), particularly in patients with T1c tumors (5-year BCSS 94.5% vs. 91.2%).